View Older Stories
-
Citizens Upgrades Progyny (PGNY) to Market Outperform
-
BofA on Progyny (PGNY): 'Positive 4Q preannouncement reflects execution and recent momentum'
-
Truist Securities Upgrades Progyny (PGNY) to Buy
-
Progyny president Michael Sturmer to step down at year-end
-
Progyny (PGNY) PT Raised to $31 at Cantor Fitzgerald: Differentiated Strategy Prime
-
KeyBanc Upgrades Progyny (PGNY) to Overweight
-
Progyny (PGNY) Tops Q3 EPS by 32c ; Offers Guidance
-
Progyny (PGNY) Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause
-
Trump: FDA will expedite review of another common IVF drug
-
Trump: Americans will be able to opt in to specialized coverage for fertility
-
Trump to announce pricing deal on IVF drugs - Axios
-
IVF stocks are gaining on report WH is moving to make it more accessible
-
Progyny (PGNY) PT Raised to $23 at Canaccord Genuity
-
Cantor Fitzgerald Reiterates Overweight Rating on Progyny (PGNY)
-
Progyny (PGNY) Tops Q2 EPS by 32c ; Offers Guidance
-
Progyny partners with ŌURA to integrate wearable health data
-
Leerink Partners Upgrades Progyny (PGNY) to Outperform, 'we see more room for upside than downside'
-
BofA Securities Reiterates Buy Rating on Progyny (PGNY)
-
BTIG Reiterates Buy Rating on Progyny (PGNY)
-
Progyny secures $200 million credit facility, raises Q2 guidance
-
Progyny (PGNY) Adds Pelvic Floor Therapy
-
Progyny (PGNY) Joins Amazon’s Health Benefits Connector Program
-
Progyny (PGNY) Appoints Elizabeth Bierbower to its Board
-
Progyny (PGNY) appoints Dr. Gloria Richard-Davis and Dr Whitney Booker to Medical Advisory Board
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Progyny (PGNY) Tops Q1 EPS by 30c; offers guidance
-
Progyny (PGNY) names Melissa Cummings as COO, Geoffrey Clapp as CPO
-
Given contract opportunity Caid stocks likely undervalued, says Cantor Fitzgerald
-
Progyny (PGNY) Adds Doula Services
-
BTIG Upgrades Progyny (PGNY) to Buy Following Recent Positive Survey Feedback
-
KeyBanc Reiterates Sector Weight Rating on Progyny (PGNY)
-
Progyny (PGNY) PT Raised to $26 at Cantor Fitzgerald
-
Progyny (PGNY) PT Raised to $23 at Canaccord Genuity
-
Progyny (PGNY) Tops Q4 EPS by 32c ; Offers Guidance
-
Progyny (PGNY) PT Raised to $28 at Jefferies
-
Progyny (PGNY) PT Raised to $30 at BofA Securities as Trump looks to expand IVF
-
KeyBanc on Progyny (PGNY) as White House Press Secretary Tweet Drives Stock
-
IVF stocks on watch as President Trump signs an executive order to expand access
-
BofA sees a better setup in this stock after 'expectations reset'
-
Progyny (PGNY) Acquires BenefitBump
-
Progyny (PGNY) Appoints Debra Morris to its Board
-
Progyny (PGNY) PT Raised to $20 at Leerink Partners
-
Kuehn Law Encourages Investors of Progyny, Inc. to Contact Law Firm
-
Progyny (PGNY) January 17.50 calls active as share price up 16.5%
-
JPMorgan Downgrades Progyny (PGNY) to Neutral
-
Progyny (PGNY) PT Lowered to $19 at Jefferies
-
Progyny (PGNY) PT Lowered to $22 at Cantor Fitzgerald
-
Truist Securities Downgrades Progyny (PGNY) to Hold
-
Progyny (PGNY) Tops Q3 EPS by 26c, provides guidance
-
The election implications for healthcare technology and distribution stocks - BofA

